A raft of new studies on cancer and exercise show clear benefits. But a question hangs over the benefits of endurance runners.

AbbVie’s telisotuzumab dizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this population lacking.

Combination treatment could also benefit patients with lung, bowel, pancreatic and other solid cancers who don’t respond to ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths worldwide ...

Scientists at UC San Francisco have discovered how pancreatic cancer cells thrive in the lungs or liver, environments that are as distinct to cells as ...

The American Society for Clinical Oncology’s Annual Meeting for 2025 is, if nothing else, absolutely overwhelming and ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Acting Secretary for Health Dr Libby Lee chairs the 20th meeting of the Cancer Coordinating Committee to discuss the response ...

HEAVY snorers could be at risk of the world’s deadliest cancer, a shock new study has revealed. Obstructive sleep apnea (OSA) ...

Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking ...

Shares of Guardant Health Inc (NASDAQ:GH) climbed 3.7% as the company announced its Shield multi-cancer detection (MCD) test received Breakthrough Device designation from the U.S. Food and Drug ...

Engaging in leisure-time MVPA linked to improved survival for various cancer types including bladder, breast, colon.